U.S. Transthyretin Amyloidosis Treatment Market Size Is Projected to Reach US$ 1,077.7 Million at a CAGR Of 52.4% Owing To Technological Developments In Robotics By 2026
SEATTLE, April 08, 2021, (PHARMIWEB) — US Transthyretin Amyloidosis Treatment Market – Insights
Transthyretin (TTR) amyloidosis is a slowly progressive condition characterized by the buildup of abnormal deposits of a protein called amyloid (amyloidosis) in the body’s organs and tissues. There are two main types of transthyretin amyloidosis: hereditary transthyretin amyloidosis (hATTR) and wild type transthyretin amyloidosis (ATTRwt). Transthyretin amyloidosis is a rare disease and treatment for the same is not available yet.
hATTR occurs due to genetic mutations in the genes responsible for manufacturing transthyretin. It is further classified into familial amyloid polyneuropathy (FAP) and familial amyloid cardiomyopathy (FAC). ATTRwt mainly affects the heart. The most common type of FAP is caused by the Val30Met variant of TTR. The symptoms of FAP are exposed after the patient crosses 30 years of age. The symptoms can also be detected as early as 20 years or as late as 80 years of age. Depending on the location, the symptoms are classified as peripheral neuropathy and autonomic neuropathy. The symptoms become more severe when excess amyloid protein starts to collect in the nerves.
To learn more about this report, request a sample copy*
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy of this report@ https://www.coherentmarketinsights.com/insight/request-sample/1919
Tafamidis (not approved in the U.S.) and Diflunisal (off-label indication) are some of the supportive treatment options for transthyretin amyloidosis and only treat symptoms of the disease. Physicians recommend liver transplant as an effective cure for familial transthyretin polyneuropathy. The approach is not recommended for familial transthyretin cardiomyopathy or wild type TTR.
US Transthyretin Amyloidosis Treatment Market: Drivers
Strong pipeline of novel drugs is also expected to aid in growth of the market. For instance, in 2018, Alnylam Pharmaceuticals, Inc.’s Patisiran and Ionis Pharmaceuticals, Inc.’s Inotersen are expected to receive approval from the U.S. Food & Drug Administration (FDA). These therapies are based on gene silencing and work by either interfering with the abnormal transthyretin formation or by silencing the gene (antisense) responsible for production of transthyretin protein. Patisiran and Inotersen are expected to generate yearly cost of six figures between US$ 200,000 and US$ 400,000.
US Transthyretin Amyloidosis Treatment Market: Restraints
High cost of therapies is expected to hinder growth of the market over the forecast period. For instance, Tafamidis, used for the treatment of familial transthyretin polyneuropathy, costs around US$ 200,000 a year.
The U.S. transthyretin amyloidosis treatment market size is expected to be valued at US$ 36.9 million in 2018 and is expected to witness a robust CAGR of 52.4% over the forecast period (2018–2026).
Figure 1. U.S. Transthyretin Amyloidosis Treatment Market Share (%), by Drug Type, 2018 and 2026
Source: Coherent Market Insights Analysis (2017)
Figure 2. U.S. Transthyretin Amyloidosis Treatment Market Share (%), by Disease Type, 2018 and 2026
Source: Coherent Market Insights Analysis (2017)
US Transthyretin Amyloidosis Treatment Market: Competitive Landscape
Major players operating in the U.S. transthyretin amyloidosis treatment market include Alnylam Pharmaceuticals, Inc., Pfizer, Inc., Prothena Corporation Plc, GlaxoSmithKline Plc, Ionis Pharmaceuticals, Inc., Eidos Therapeutics, and SOM Innovation Biotech, S.L.
US Transthyretin Amyloidosis Treatment Market: Key Developments
Major players in the market are focused on conducting clinical trials to expand their product portfolio. For instance, in March 2018, Pfizer, Inc. reported positive results from Phase 3 ATTR-ACT study of Tafamidis among patients suffering from transthyretin cardiomyopathy. Similarly, by 2018 (between Q3 and Q4), Alnylam Pharmaceuticals, Inc. is expected to initiate phase 3 clinical trials for ALN-TTRsc02 for the treatment of ATTR amyloidosis.
Access research reports that are tailored specifically for you and your organization in order to explore practical growth strategies and recommendations
Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/1919
Table of Contents
- Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Technology
- Market Snippet, By Disease Indication
- Market Snippet, By End User
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Clinical Characteristics
- Disease Diagnosis
- Epidemiology
- Transthyretin Amyloidosis Treatment Overview
- PEST Analysis
- PORTER’s Analysis
- Therapy Study (Mechanism of Action)
- Market Dynamics
- U.S. Transthyretin Amyloidosis Treatment Market, By Drug, 2016–2026 (US$ Mn)
- Introduction
- Market Share Analysis, 2018 and 2026 (%)
- Y-o-Y Growth Analysis, 2017–2026
- Segment Trends
- Tafamidis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
- Diflunisal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
- Patisiran
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
- Inotersen
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
- Introduction
- U.S. Transthyretin Amyloidosis Treatment Market, By Disease Type, 2016–2026 (US$ Mn)
- Introduction
- Market Share Analysis, 2018 and 2026 (%)
- Y-o-Y Growth Analysis, 2017–2026
- Segment Trends
- Hereditary Transthyretin Amyloidosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
- Polyneuropathy
- Cardiomyopathy
- Mixed Type
- Wild Type Amyloidosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
- Introduction
- U.S. Transthyretin Amyloidosis Treatment Market, By Distribution Channel, 2016–2026 (US$ Mn)
- Introduction
- Market Share Analysis, 2018 and 2026 (%)
- Y-o-Y Growth Analysis, 2017–2026
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
- Introduction
- Competitive Landscape
- Company Profiles
- Section
- References
- Research Methodology
- About Us and Sales Contact
View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/us-transthyretin-amyloidosis-treatment-market-to-surpass-us-10777-million-threshold-by-2026-999
About Us:Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
Editor Details
-
Company:
- CDN Newswire
